Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Orexo announces positive results from ISTART/006 study

Orexo announces positive results from ISTART/006 study

Orexo US, Inc. announced results from the ISTART/006 study, being presented today at the 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry in Aventura, Florida, USA. [More]
Researchers figure out how to reverse characteristics of polyurea materials

Researchers figure out how to reverse characteristics of polyurea materials

Researchers at the University of Illinois at Urbana-Champaign have figured out how to reverse the characteristics of a key bonding material--polyurea--providing an inexpensive alternative for a broad number of applications, such as drug delivery, tissue engineering, and packaging. [More]
New light-triggered strategy can provide accurate control over aptamer-based therapeutics

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels. [More]
BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX submits request for pre-IND meeting to FDA for topical antibiotic acne compound

BioPharmX Corporation, a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has submitted a request for a pre-IND (Investigational New Drug) meeting to the U.S. Food and Drug Administration for the company's topical antibiotic acne compound currently under development. [More]
iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]

Hovione submits first IND Application with FDA for minocycline gel

Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs. [More]
Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

Interventional X-ray guidance device may reduce radiation exposure of liver cancer patients

Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer. [More]
New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million. [More]
Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

Bayer's Amikacin Inhale and Ciprofloxacin DPI receive QIDP designation from FDA

The U.S. Food and Drug Administration has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI). [More]
Researchers make significant breakthrough for sufferers of bone disease

Researchers make significant breakthrough for sufferers of bone disease

Researchers in bone tissue regeneration believe they have made a significant breakthrough for sufferers of bone trauma, disease or defects such as osteoporosis. [More]
WSU researchers working on new system to reduce negative effects of cancer drugs

WSU researchers working on new system to reduce negative effects of cancer drugs

Wichita State University researchers are working on a new system that could decrease the negative effects of cancer drugs on patients. [More]

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy. [More]
Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors. [More]
Platelet-like nanoparticles mimic human body's coagulation process

Platelet-like nanoparticles mimic human body's coagulation process

Stanching the free flow of blood from an injury remains a holy grail of clinical medicine. Controlling blood flow is a primary concern and first line of defense for patients and medical staff in many situations, from traumatic injury to illness to surgery. [More]
U of G research may lead to novel treatment approaches for late-stage ovarian cancer

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

In a potential breakthrough against ovarian cancer, University of Guelph researchers have discovered how to both shrink tumours and improve drug delivery, allowing for lower doses of chemotherapy and reducing side effects. [More]

New multi-specimen perfusion bioreactor for reliable tissue growth introduced by Bose

Bose Corporation has introduced the 3DCulturePro™ system, a new multi-specimen perfusion bioreactor designed for biologists, biomedical researchers and scientists who require reproducible and reliable tissue growth. The 3DCulturePro system supports cell growth and 3D tissue culture in an easy-to-use, scalable configuration. [More]

Unilife submits 10-Q report for first quarter of FY 2015

Unilife Corporation ("Unilife" or "Company"), a developer and supplier of injectable drug delivery systems, today announced that it has submitted for filing its 10-Q report for the first quarter of Fiscal Year 2015 ending September 30, 2014. [More]
BioInfect 2014 conference explores global anti-microbial agenda

BioInfect 2014 conference explores global anti-microbial agenda

This year’s unique BioInfect conference organised by Bionow, a not for profit membership organisation for the biomedical / life-sciences industry,was a major success. [More]
Liposomes can help prevent bacterial toxins from killing human cells

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells. [More]
Ipsen receives approval from FDA for new device designed to deliver Somatuline Depot Injection

Ipsen receives approval from FDA for new device designed to deliver Somatuline Depot Injection

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that the U.S. Food and Drug Administration (FDA) has approved a new device to deliver Somatuline Depot (lanreotide). The device has an enhanced, prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements. [More]